We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more call options, than puts

Call options by funds: $805K | Put options by funds: $456K

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

4% more funds holding

Funds holding: 113 → 118 (+5)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

1% less capital invested

Capital invested by funds: $216M → $213M (-$2.47M)

Holders
118
Holders Change
+5
Holders Change %
+4.42%
% of All Funds
1.86%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
38
Reduced
25
Closed
17
Calls
$805K
Puts
$456K
Net Calls
+$349K
Net Calls Change
+$956K

Top Buyers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
+$1M
2
Millennium Management
Millennium Management
New York
+$950K
3
Citadel Advisors
Citadel Advisors
Florida
+$883K
4
Renaissance Technologies
Renaissance Technologies
New York
+$768K
5
HS
HighVista Strategies
Massachusetts
+$653K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.3M
2
SCM
Stonepine Capital Management
Oregon
-$1.01M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$663K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$361K
5
NCM
Nantahala Capital Management
Connecticut
-$334K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
101
Citigroup
New York
$17K -$47.9K -15,220 -73%
Nisa Investment Advisors
102
Nisa Investment Advisors
Missouri
$17K -$15.7K -5,000 -48%
Simplex Trading
103
Simplex Trading
Illinois
$17K +$17.5K +5,574 New
Royal Bank of Canada
104
Royal Bank of Canada
Ontario, Canada
$16K -$26.7K -8,482 -62%
PHK
105
Point72 Hong Kong
Hong Kong
$8K +$7.92K +2,517 New
QT
106
Quantbot Technologies
New York
$5K – – –
GRP
107
Global Retirement Partners
California
$2K – – –
PNC Financial Services Group
108
PNC Financial Services Group
Pennsylvania
$2K – – –
SPIA
109
Steward Partners Investment Advisory
New York
$2K – – –
QCG
110
Quadrant Capital Group
Ohio
$1K +$1.37K +435 New
AGM
111
Alpine Global Management
New York
$778 – – –
Point72 Asset Management
112
Point72 Asset Management
Connecticut
– -$2.3M -681,401 Closed
SCM
113
Stonepine Capital Management
Oregon
– -$1.01M -300,000 Closed
Massachusetts Financial Services
114
Massachusetts Financial Services
Massachusetts
– -$663K -196,052 Closed
Federated Hermes
115
Federated Hermes
Pennsylvania
– -$262K -77,403 Closed
CAC
116
Cowen and Company
New York
– -$222K -65,600 Closed
SCP
117
Sender Company & Partners
New York
– -$206K -61,080 Closed
Bank of Montreal
118
Bank of Montreal
Ontario, Canada
– -$56K -16,904 Closed
B
119
Bailard
California
– -$46K -13,700 Closed
AC
120
Apogem Capital
New York
– -$44K -12,924 Closed
OQS
121
Occudo Quantitative Strategies
Florida
– -$41K -12,051 Closed
DTL
122
Dynamic Technology Lab
Singapore
– -$37K -11,074 Closed
Squarepoint
123
Squarepoint
New York
– -$35K -10,273 Closed
VRM
124
Vectors Research Management
New York
– -$20K -6,000 Closed
EWA
125
EverSource Wealth Advisors
Alabama
– -$4K -1,050 Closed
2 3 4
5
6

CBAY Hedge Fund Activity: Q1 2022 in Review

118 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2022, worth a combined $213M — down 1.1% from $216M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new CBAY positions and 17 closed out — a net gain of 5 holders — while 38 added to existing stakes and 25 trimmed.

The largest buyer was Commodore Capital, adding an estimated $1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.3M sold.

  • 118 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2022, up from 113 in Q4 2021.
  • Funds reported $213M of Cymabay Therapeutics stock for Q1 2022, down 1.1% quarter-over-quarter.
  • 22 funds opened new Cymabay Therapeutics positions in Q1 2022 and 17 closed out, a net change of +5 holders.
  • The largest Cymabay Therapeutics buyer in Q1 2022 was Commodore Capital, an estimated $1M added.
  • The largest Cymabay Therapeutics seller in Q1 2022 was Point72 Asset Management, an estimated $2.3M sold.

Based on aggregated 13F filings for Q1 2022.